Photo Credit: Henadzi Pechan
The following is a summary of “Lifitegrast in Treatment of Dry Eye Disease—A Practical, Narrative Expert Review,” published in the January 2025 issue of Ophthalmology by Landsend et al.
Dry eye disease (DED), a multifactorial disorder affecting millions globally, characterized by a central role of inflammation.
Researchers conducted a retrospective study to critically evaluate the literature on the efficacy and safety of lifitegrast, a small molecule immunomodulator that blocked the action of lymphocyte function-associated antigen-1.
They identified studies from PubMed and ClinicalTrials.gov, selecting 14 that met the inclusion criteria, including 6 randomized controlled trials. The studies were evaluated for lifitegrast’s impact on DED symptoms and signs, its comparison with other treatments, and potential adverse events.
The results showed the lifitegrast had positive effects on both subjective and objective DED parameters in the selected studies. However, despite encouraging findings, the evidence was insufficient to confirm that lifitegrast was superior to other DED treatments with no significant side effects.
Investigators concluded the lifitegrast could improve various DED parameters, but larger controlled trials were needed to establish its additional benefits over other DED treatments.
Source: onlinelibrary.wiley.com/doi/full/10.1155/joph/6504111
